InSilixa, a Sunnyvale, California-based molecular diagnostic (MDx) platform developer, raised a $13M financing round.
The round was led by PointGuard Ventures and Morningside. In conjunction with the funding, Pete Thomas, Managing Director, PointGuard Ventures; and Dr. Gerald Chan, co-founder of Morningside, joined InSilixa’s board.
The company intends to use the funds to progress its point-of-care technology.
Founded by CEO Arjang Hassibi, Ph.D., InSilixa leverages proprietary semiconductor-based CMOS biochip technology to develop point-of-care (PoC) and near patient platforms for the delivery of mass-deployable solutions for DNA and protein-based diagnostic testing.
The technologies behind its products came out of Caltech, The University of Texas at Austin, and Stanford University.
FinSMEs
22/10/2014